What is B. Riley’s Forecast for NKTR FY2024 Earnings?

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at B. Riley issued their FY2024 earnings per share (EPS) estimates for Nektar Therapeutics in a note issued to investors on Tuesday, January 7th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will earn ($0.83) per share for the year. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

NKTR has been the topic of several other reports. BTIG Research reiterated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler began coverage on Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price on the stock. Finally, HC Wainwright started coverage on shares of Nektar Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $6.50 price objective for the company. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Price Performance

Shares of Nektar Therapeutics stock opened at $1.14 on Friday. Nektar Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.93. The firm has a market capitalization of $210.28 million, a PE ratio of -1.36 and a beta of 0.59. The company’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.21.

Insider Buying and Selling at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $0.94, for a total value of $48,048.10. Following the completion of the transaction, the insider now owns 326,904 shares of the company’s stock, valued at $307,289.76. The trade was a 13.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard W. Robin sold 46,995 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares of the company’s stock, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock worth $149,878 over the last 90 days. Company insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Hedge funds have recently made changes to their positions in the company. Samlyn Capital LLC acquired a new stake in Nektar Therapeutics in the second quarter valued at $11,728,000. Eventide Asset Management LLC grew its position in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after buying an additional 1,870,904 shares during the last quarter. Millennium Management LLC increased its stake in shares of Nektar Therapeutics by 56.1% in the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after buying an additional 1,674,924 shares during the period. Nantahala Capital Management LLC raised its position in shares of Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in shares of Nektar Therapeutics in the second quarter worth approximately $1,037,000. 75.88% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.